A phase I trial of EPZ-5676 recently opened for pediatric patients with relapsed/refractory leukemias bearing a rearrangement of the MLL gene (ClinicalTrials.gov identifier: NCT02141828). This evidence concerns the gene KMT2A and leukemia.